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Background: Complex molecular events lead to development and progression of liver cirrhosis to HCC.
Differentially expressed nuclear membrane associated proteins are responsible for the functional and structural
alteration during the progression from cirrhosis to carcinoma. Although alterations/ post translational modifications
in protein expression have been extensively quantified, complementary analysis of nuclear membrane proteome
changes have been limited. Deciphering the molecular mechanism that differentiate between normal and disease
state may lead to identification of biomarkers for carcinoma.
Results: Many proteins displayed differential expression when nuclear membrane proteome of hepatocellular
carcinoma (HCC), fibrotic liver, and HepG2 cell line were assessed using 2-DE and ESI-Q-TOF MS/MS. From the
down regulated set in HCC, we have identified for the first time a 15 KDa cytochrome b5A (CYB5A), ATP synthase
subunit delta (ATPD) and Hemoglobin subunit beta (HBB) with 11, 5 and 22 peptide matches respectively.
Furthermore, nitrosylation studies with S-nitrosocysteine followed by immunoblotting with anti SNO-cysteine
demonstrated a novel and biologically relevant post translational modification of thiols of CYB5A in HCC specimens
only. Immunofluorescence images demonstrated increased protein S-nitrosylation signals in the tumor cells and
fibrotic region of HCC tissues. The two other nuclear membrane proteins which were only found to be nitrosylated
in case of HCC were up regulated ATP synthase subunit beta (ATPB) and down regulated HBB. The decrease in
expression of CYB5A in HCC suggests their possible role in disease progression. Further insight of the functional
association of the identified proteins was obtained through KEGG/ REACTOME pathway analysis databases. String
8.3 interaction network shows strong interactions with proteins at high confidence score, which is helpful in
characterization of functional abnormalities that may be a causative factor of liver pathology.
Conclusion: These findings may have broader implications for understanding the mechanism of development of
carcinoma. However, large scale studies will be required for further verification of their critical role in development
and progression of HCC.
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Hepatocellular carcinoma (HCC) is the third leading
cause of cancer related deaths worldwide [1-4], increas-
ing from 1.8 to 2.5 per 100,000 patients. Hepatitis B and
C viral infections are well recognized underlying cause
of chronic liver disease leading to HCC whereas dietary
exposure to aflatoxin B1, alcoholic liver dysfunction and
autoimmune hepatitis are also renowned risk factors
[5-9]. The prognosis of HCC is dismal due to underlying
cirrhosis as well as poor tumor response to chemothera-
peutic regimens [10-12]. Opportunity for anti-cancer
therapy in early stage is overlooked just because of the
lack of effective biomarkers [13,14]. Complex molecular
events lead to development and progression of liver cir-
rhosis to HCC. Deciphering the molecular mechanism
that differentiates between normal and disease state may
lead to identification of biomarkers for carcinoma [15,16].
Although alterations in protein expression have been ex-
tensively quantified during progression from cirrhosis to
carcinoma, complementary analysis of nuclear membrane
proteome changes has been limited [17].
HCC has been associated with elevated expression of
inducible nitric oxide synthase (iNOS), and has been
responsible for high-output production of nitric oxide
(NO). Innate immune response and inflammation,
NO is often highly increased at mRNA and protein
levels in patients with chronic HBV and HCV [18-20],
hemochromatosis and alcoholic cirrhosis [20] all of
which cause predisposition to HCC [21]. Nitrosylation
is essential and an important reversible post transla-
tional modification (PTM) of proteins [22-24]. It is a
potential modulator of cellular processes important for
tumorigenesis, apoptotic cell death and inhibition of
DNA repair [25-27]. In addition to phosphorylation,
DNA repair pathways are regulated at multiple
levels by NO key components that depict an import-
ant role in pathogenesis of hepatocellular carcinoma
[25,28-30].
Here we interrogate the differential proteome profiling
in HCC tissues of clinically diagnosed HCC patients, fi-
brotic liver and HepG2 cell lines as controls. We ex-
plored HCC nuclear membrane CYB5A as down
regulated and nitrosylated. The altered expression of
CYB5A suggests that these proteins may be used as a
novel prognostic factor and possibly an attractive target
for HCC. CYB5A has been associated with essential cel-
lular processes that include cytochrome P450 mediated
metabolism of xenobiotics, drugs [31-34], and homeosta-
sis of cholesterol and steroid hormone [35-37]. Involve-
ment of CYB5A in methemoglobin to hemoglobin
reduction in erythrocytes [38], and hydroxylation of
N-acetyl-neuraminic acid is also observed [39]. Add-
itionally, naturally existing fusion enzymes include mito-
chondrial flavocytochrome b2 (L-lactate dehydrogenase)[40], sulfite oxidase [41], the Δ 5 and Δ 6 -fatty acid desatu
rases (stearyl-CoA-desaturase) [42] and yeast inosi
tolphosphorylceramide oxidase also contains CYB5A
as a domain component [43].
Results
Differential assessment of HCC proteome
In an effort to profile differentially expressed proteomic
alterations in HCV infected liver during cancer progres-
sion, we used 2-DE coupled with ESI-QTOF MS/MS to
determine the relative levels of proteins across HCC and
fibrotic liver.
Approximately 864 protein spots were detected on
2DE gels, out of which 76 protein spots exhibit differen-
tial expression in HCC as compared to fibrotic liver and
HepG2 cell line. The quantity of each spot was normal-
ized as a percentage of the total quantity of all gel spots.
Differentially expressed proteins were defined as statisti-
cally significant on the basis of >1.5 fold up and down
regulation in HCC patients compared with cell line or
more changes in expression intensity (p < 0.05). Gel ana-
lysis was performed using Progenesis SameSpots v4.5
(Nonlinear Dynamic, UK). Each sample set (n = 6) was
analyzed in 5 independent mass spectrometer runs.
The data revealed, for the first time, additional pro-
teins that were dysregulated in HCC compared with
fibrotic liver and HepG2 cell line. These include signifi-
cantly elevated levels of ATPB, fibrinogen beta chain
(FIBB), and cytochrome b-c1 complex subunit 1(QCR1).
Included among the proteins that were down-regulated
and not previously reported were CYB5A, ATPD and
HBB well represented in Figure 1A. The protein spots
were analyzed by using ESI-QTOF MS/MS. Total of six
proteins along with accession no. obtained from SWISS/
Prot and sequence coverage (%) refers to the percentage
of protein sequence coverage, determined by number of
matched peptides, and their functions were described in
Table 1, Additional file 1. Due to the functional signifi-
cance of CYB5A, we focused on the decreased expression
of CYB5A observed in HCC as compared to fibrotic liver.
The protein expression along with MS/MS spectra and
matched sequence are shown in Figure 1(B-D). In order to
assess the validity of data, we examined the differentially
expressed CYB5A protein by western blot. The expression
of CYB5A was seen to be relatively down regulated in
HCC as compared to HepG2 cell line and fibrotic liver
Figure 2(A-B).
CYB5A is an S-Nitrosylated protein
CYB5A a key determinant of our study was observed to
be differentially S-nitrosylated in HCC, fibrotic liver and
even HepG2 cell lines. An increased intensity of S-
nitrosylation in the fibrotic tissue is revealed by 2-DE-IP
and western blot analysis, relatively low intensity in
Figure 1 Targeting CYB5A as potential biomarker. (A): in this representative expression profile of significantly up (ATPB, FIBB, and QCR1) and
down regulated (CYB5A, ATPD and HBB) proteins in HCC compared with fibrotic liver and HepG2 cell line. Focused on IPG strips pH 3–11 NL (11
cm) and separated on 12.5% gels followed by silver staining. Gel analysis was performed by using Progenesis SameSpots v4.5 (Nonlinear
Dynamic, UK). The statistical analysis using Student t-test was performed and on the basis of normalized volumes spots were selected with
p-values (< 0.05). (B): Representative protein spot of CYB5A (indicated by circle), showing differential expression between HCC, fibrotic liver and
HepG2 cell line. The protein spots were analyzed by using ESI-QTOF MS/MS. (C): Representative MS/MS spectrum and peptide sequence of
CYB5A identified by one or more high scoring peptides were considered to be true matches or with extensive homology (p < 0.05). b and y
represent b ions and y ions respectively, generated during peptide fragmentation in MS/MS. (D): Amino acid sequence of CYB5A, matched
peptides were expressed in red type and underline.
Khan et al. Clinical Proteomics 2013, 10:6 Page 3 of 12
http://www.clinicalproteomicsjournal.com/content/10/1/6HCC and very low in case of cell lines Figure 3(A-B)
respectively.
Immunohistolocalization of CYB5A
IHC analysis of the CYB5A shows significant expression
in malignant hepatocytes. However, no expression was
observed in portal vein Figure 4(A-B). We also studied
disseminated intravascular coagulation (DIC) images,
created with Adobe Photoshop CS2 images that exposed
the histology and morphology of cells on the same sec-
tions. Both immunofluorescence and DIC images were
stacked in Figure 4(B). All information related to micro-
scope and camera setting is provided in the supplemen-
tary data (Additional file 2).
Immunohistolocalization of S-nitrosylated protein
Increased S-nitrosylation signal was observed in tumor
and fibrous region of HCC tissue as compared to con-
trols Figure 5(A, B & C). A significant increase in
S-nitrosylation intensity of CYB5A is also evident in this
regions (Tumor and Fibrosis), revealed by immunofluor-
escence images Figure 5(C, D & E). The results presents
a massive disruption of lobular manner, portal tract ex-
pansion with inflammatory cells in the sinusoids, lymph-
oid aggregate and hepatocellular apoptosis in the regionswith hyper S-nitrosylation signals. The histological and
morphological defects were assessed in these regions
using Hemotoxylin and Eosin (H&E) staining prior to
the immunoflorescence analysis.
The predicted functional association network of CYB5A
The functional association network of the identified
proteins was generated through protein interaction
network STRING 8.3. The interaction patterns will be
helpful to have a better understanding of the protein
functional activities. As the identified proteins are in-
volved in various cellular/metabolic pathways the close
interaction pattern, evident with the high confidence
score > 0.7 are helpful to explicate disease related con-
sequences due to structural and functional perturba-
tions of the expressed protein Figure 6. CYB5A is a
membrane bound hemoprotein strongly interacting
with its class member CYB4R3 (cytochrome b5 reduc-
tase 3), CYP17A1 (Cytochrome P450 family 17, sub-
family A, polypeptide 1), CYP3A5 (Cytochrome P450
family 3, subfamily A, polypeptide 5). Possible strong
interaction with FADS2 (fatty acid desaturase 2), SCD
(stearoyl-CoA desaturase), ACSL1, L2, L3 and L4
(acyl-CoA synthetase, long chain family member 1, 2,
3and 4 respectively) are also observed Figure 6.
Table 1 Differentially expressed HCC, fibrotic liver nuclear membrane proteins and HepG2 cell line
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Accession no. is obtained from SWISS/Prot and percent coverage refers to the percentage of protein sequence coverage, determined by number of matched
peptides. Significance was calculated from the Progenesis SameSpots v4.5 (Nonlinear Dynamic, UK), generated statistical analysis. A value of p < 0.05 was
considered statistically significant. Functional classes were determined by searching the UniProt database (www.uniprot.org).
The proteins were separated on 2DE gels and identified by ESI-QTOF MS/MS.
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Having validated our Mass spectrometry result of
CYB5A, we delineated the biological function associa
ted with this elevated protein alterations based on the
known protein functions according to SWISS-PROT
(http://www.expasy.org), classifications provided in the
KEGG database (http://www.genome.jp/kegg), GO anno-
tation (http://www.geneontology.org), Reactome, Uniprot,
ENSEMBL, PINC analysis pathway and Panther classifica-
tion system. This process allowed us to identify pathways
that are deregulated during HCC development and pro-
gression. This exercise revealed the involvment of CYB5Ain vitamin C (ascorbate) metabolism, metabolism of
water-soluble vitamins and cofactors, metabolism of
vitamins and cofactors, transport, L-ascorbic acid meta-
bolic process, electron transport chain, small mole
cule metabolic process, aldo-keto reductase (NADP)
activity, amino sugar and nucleotide sugar metabolism
http://www.reactome.org.
Discussion
The current study identifies novel nuclear membrane
biomarkers for HCC. Out of 76 differentially expressed
proteins, six proteins ATPD, FIBB, ATPB, HBB, CYB5A,
Figure 2 Immunoblot analysis confirms changes in protein expression of CYB5A. (A): representative western blot analysis of CYB5A in HCC,
fibrotic liver and HepG2 cell line. For this, 100μg of nuclear membrane samples were loaded onto a 12% SDS-PAGE. Expression level was analyzed
using the primary antibody CYB5A (1:1000 dilution) and horse raddish peroxidase (HRP) - conjugated secondary antibody (1: 5000 dilution).
Β-actin and GAPDH were used as a loading control. (B): representative graphical expression of validated proteins by western blotting. Digital
images were taken by gel documentation system (Bio-Rad). Quantification and intensity measurement of protein bands were analyzed by
Quantity One gel analysis software (Bio-Rad). Statistical significance (p- value > 0.05) was calculated using SPSS statistics version 17.
Figure 3 Antibody based identification of CYB5A as S-nitrosylated protein. (A): 2DE Spot representative differential expression level of
CYB5A as S-nitrosylated protein in HCC compared with respective fibrotic liver and HepG2 cell line. The proteins were immuno-precipitated with
anti SNO-Cys antibody, focused on IPG strips (pI 3-11NL; 7 cm) and separated on 12.5% gel followed by silver staining. (B): Representative spots
of CYB5A immuno-precipitated with anti SNO-Cys antibody. 100 μg proteins were focused using pI 3-11NL (7 cm) IPG strips and separated on
12.5% gel followed by western blotting described in material and methods. Densitrometric analysis was performed using Progenesis SameSpots
v4.5 (Nonlinear Dynamic, UK).
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Figure 4 Immunofluorescence analysis of CYB5A in HCC. The IHC image of CYB5A staining in control (A) and hepatocellular carcinoma (C &
E) formalin fixed paraffin embedded (FFPE) section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer
for 30min. The section was then incubated with CYB5A, 5 μg/ml, for 1hr at 40oC. The secondary antibody (green) was Alexa Fluor® 488 goat
anti-mouse IgG (H+L) used at a 1/1000 dilution for 30min at 40oC. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43 μM.
(B, D & F): combination of DIC images and IHC of control and HCC respectively, work done by Adobe Photoshop CS2. (C=Portal tract; H=Normal
hepatocytes; T=Malignant hepatocytes; Original magnification= 20X). IHC: Immunohistolocalization.
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delineated into liver fibrosis and carcinoma specific pro-
teins. CYB5A trapped our main focused not only be-
cause of lack of information regarding its sub cellular
location and down regulation in nuclear membrane of
HCC compared to fibrotic liver and HepG2 cell lines, but
also because of S-nitrosylation of this protein. Interest-
ingly, CYB5A is characterized by the presence of 3 well-
defined phosphorylation sites as demonstrated by the
insilico analysis (NetPhosK 1.0). It is likely that incomplete
phosphorylation, (may be due to nitrosylation) i.e. not all
monomers are phosphorylated, may interfere with protein
function. Emerging data suggests that CYB5A and othernuclear proteins are involved in HCC progression [44-46].
Further study will be required to clarify how phosphoryl-
ation and nitrosylation influence HCC and the consequent
expression of proteins.
Validation by western blotting, immunoprecipitation
and immunohistochemical studies revealed the charac-
terized pattern in malignant cells and nuclei but was ab-
sent in portal tract. These results allow us to propose
sub cellular localization of CYB5A as down regulated
nuclear membrane protein with a mechanism proposed
in various pathophysiological conditions as aberrant S-
nitrosylation, caused by altered NO production. So we
can say that, decreased expression could leave the liver
Figure 5 Evidence of S-nitrosylation in HCC: Increased S-nitrosylation is evident in the fibrous portion and tumor cells in HCC. Anti
SNO-Cys antibody was used to reveal the distribution of S-nitrosylation signals in the HCC and controls. Significant increase CYB5A is also evident
in both fibrous and tumor cells similar to S-nitrosylation. Figure A & D represents control liver on the other side B, C, E, F explained strong
S- nitrosylation signals in HCC.
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Additional study is needed to determine whether NO
production induces post-translational modifications of
protein and modulates protein function in HCC cell.
However, due to the absence of cysteine residue in the
CYB5A protein sequence, we propose that the other thiol
groups are nitrosylated in the studied HCC specimens.Figure 6 Functional association network of CYB5A. High-confidence pr
proteins derived from the STRING database (http://string-db.org/). Each pro
cytochrome b5 reductase 3; CYP17A1: Cytochrome P450 family 17 subfami
polypeptide 5; FADS2: fatty acid desaturase 2; SCD: stearoyl-CoA desaturase
1, 2, 3 and 4 respectively).Understanding towards the disease progression requires
complete knowledge interrelated to different pathways and
their involvement with the altered proteins.
We conducted STRING 8.3 generated patterns which
demonstrated direct interaction of these metabolic pro-
teins with other associated proteins, CYB4R3, CYP17A1,
CYP3A5 FADS2 SCD and ACSL1, has an essential roleotein-protein interaction network of identified nuclear membrane
tein is represented as a node with edged interactions. (CYB4R3:
ly A polypeptide 1; CYP3A5: cytochrome P450 family 3, subfamily A,
; ACSL1, L2, L3 and L4: acyl-CoA synthetase, long chain family member
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steroids, catabolism of xenobiotics and endogenous me-
tabolism [47]. It also has a rather complex interaction
with Cytochrome P450 and stimulates its related metab-
olism [33,48,49].
Insilico studies revealed the role of CYB5A in aldo-
keto reductase (NADP) activity, cytochrome-c oxidase
activity, enzyme binding, heme binding as reflected by the
KEGG/REACTOME pathway analysis. Its involvement in
respiratory electron transport chain, lipid metabolic
pathway was further elaborated by Panther classification
(www.panther.com). Several lines of evidence provide
insight into potential mechanism by which CYB5A may
affect HCC progression and associated pathological condi-
tion [25,27]. In our case, the presence of 15 -KDa CYB5A
fragment in the HCC specimens compared to fibrotic liver
and HepG2 cell lines clearly indicates the possible role of
this protein in cancer progression. The novel discovery of
a membrane protein CYB5A down regulation and its
localization coupled with the observation of intense
nitrosylation signals in the regional architecture of cir-
rhotic tissue strongly suggests a major role of CYB5A in
the physiology and pathophysiology of HCC.
Conclusion
Our study suggests that nuclear membrane proteins may
have a role in progression from fibrosis to liver carcino-
genesis. The molecular mechanisms controlling CYB5A
expression and function are of paramount importance.
Moreover, target protein activation may be influenced by
nitrosylation, might represent a mechanism insuring that
a cirrhotic tissue development process was underway
where CYB5A and other different proteins can be ap-
plied to post translation regulation. In this regard recent
studies are beginning to establish biochemical connec-
tions between different proteins and cell signaling mole-
cules. Further work must be performed to determine
whether these changes are essential and appropriate for
HCC diagnosis and prognosis.
Material and methods
Tissue procurement
The Institutional Review Board of University of Kansas
Medical Center (USA) and University of Karachi,
Pakistan approved this study on discovery of nuclear
membrane proteome of liver cancer. Well characterized
HCV-associated HCC liver tissues (n = 50) were by
Kansas Medical Center (KUMC) Liver Bank, USA and
Karachi hospitals [male 25 age in mean + SD 53 ± 7.06);
female = 25 (51.1 ± 3.35)] while the fibrotic liver tissue
[n = 65; male = 45 (49.4 ± 5.8) & female = 20 (47.4 ± 5.4)]
were collected only from Karachi, Pakistan with con-
firmed clinical and genotype report. Tissues were snap-
frozen in dry ice and stored at −80°C.Extraction of protein from HCV infected liver
For protein extraction, samples [HCC (n = 50) fibrotic
liver (n = 65)] were immersed into PBS (phosphate buffer
saline) buffer and washed. Homogenized in adequate
volume of homogenization medium (0.25 M sucrose and
10 mM HEPES, pH 7.5), and centrifuged at 1000xg for
10 min. The pellet and supernatant were collected and
the supernatant resuspended with buffer A (0.3 M
sucrose, 50 mM tris, and 3 mM MgCl2, pH 7.5) and buf-
fer B (1.98 M sucrose, 50 mM tris, 1 mM MgCl2,
pH 7.5), centrifuged at 70,000xg for 90 min (Optima L-
100 XP, Beckman Coulter, USA).Protease (Cocktail tab-
let, Roche, Germany) and phosphatase inhibitors
(0.2 mM sodium orthovanidate Na3Vo4 and 1 mM so-
dium fluoride NaF) were added at every step [17]. The
pellet containing nuclei fraction was collected and
resuspended in lysis buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 30 mM tris-Cl, pH 8.5, protease inhibitor mix-
ture), stored at −80°C. Total protein content was mea-
sured using the Bradford protein assay.
Cell culture and cell lysis
HepG2 cell line grown in Dulbecco’s modified Eagle
medium (DMEM) containing 10% fetal calf serum (FCS)
was used. Briefly, cells were rinsed with DMEM and re-
moved from the flask by incubating with a solution
containing trypsin (0.5 g/l) and EDTA (0.2 g/l). The cells
were detached from the surface of the flask by squirting
the solution onto the cells. The suspension was
centrifuged at 1000xg for 5 min and the cells washed
with DMEM without FCS. After centrifugation and re-
moval of DMEM, cells were mixed and solubilized. The
cells were washed twice by centrifugation in PBS and
transferred to sterile tubes for storage at −80°C until fur-
ther analysis.
Two dimensional gel electrophoresis (2DE)
Isoelectric focusing was performed on Multiphor II system
(Amersham GE-Health, Sweden). Briefly, 300 μg nuclear
membrane protein of HCC, fibrotic liver and HepG2
cell line were dissolved in rehydration buffer (7 M urea,
2 M Thiourea, 4% CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate), 0.2% Ampholyte,
15 mM DTT (Dithiothreitol) and trace amount of
bromophenol blue) and applied to IPG strips (11 cm,
pH 3–10, NL) allowing to rehydrate overnight. The focus-
ing was carried out at 20°C, following gradient change in
voltage: 500 V for 1 h, gradient up to 1000 V over 1 h, gra-
dient to 5000 V over 1 h, and focusing was continued at
5000 V for 8.5 h to give a total of 64kVh. Later the IPG
strips were subjected to a two step reduction and alkyl-
ation by equilibrating the strips for 20 min in 50 mM
Tris–HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS,
bromophenol blue, and 0.5% DTT, followed by another
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cerol, 2% SDS (sodium dodecyl sulphate), bromophenol
blue and 4.5% iodoacetamide (IAA) at room temperature.
Second dimension was conducted in 1 mm thick 12.5%
polyacrylamide gels at 100 V for 6 h. The gels were visual-
ized by silver staining [50], each sample were performed in
triplicate. Digital images of the gels were taken by gel
documentation system (BioRad, USA).
Western blotting
Nuclear fractionated proteins (100 μg) were trans-
ferred electrophoretically (100 V for 4 hr) onto PVDF
(Polyvinylidene fluoride) membrane (Amersham, GE
Health, Sweden). The membranes were blocked with 5%
BSA (bovine serum albumin) for 1 h at 4°C and incubated
overnight with primary antibody anti- cytochrome b5A
(ABCAM-UK) (1:1000 dilutions). The blots were washed
three times with TBST (Tris-buffered saline with Tween)
buffer and incubated for 1 hr at 4°C with goat polyclonal
rabbit IgG (ABCAM-UK) (1: 5000 dilutions). Immuno-
blots signals were developed by chromomeric substrate-3,
3’-diaminobenzidine (DAB, Sigma-UK).
Immunoprecipitation and 2DE (IP-2DE)
Tissue homogenates were prepared with hand ho-
mogenizer (Pyrex, Japan) by suspending the tissues in lysis
buffer (7 M urea, 2 M thiourea, 0.4% CHAPS) `containing
protease and phosphatase inhibitors (Roche, Germany).
Sepharose G beads suspension (50 μl) (Protein-G sephar-
ose 4 fast Flow, GE Healthcare, Life Sciences, Sweden),
was centrifuged at 2000–3000 rpm for 2 min. The pellet
was mixed with 450 μl HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer (50 mM HEPES
pH 7.6, 200 mM NaCl, 0.4% CHAPS) and centrifuged
again. The washing steps were repeated four times and
HEPES buffer (450 μl) was added to the pellet and vor-
tex again. Protein extract (0.4 mg/ml) was diluted with
HEPES buffer to a final volume of 300 μl and washed
protein G sepharose (200 μl) was added and incubated
for 30 min at 4°C with continuous shaking. The sample
was then centrifuged at 13000 rpm at 4°C for 5 min.
The supernatant was incubated overnight with 5 μl of
anti-S-nitroso-cysteine (SNO-Cys) antibody (ABCAM,
UK) at 4°C. Activated protein G sepharose beads
(140 μl) was added and mixed for 4 h at 4°C with con-
tinuous shaking and centrifuged for 2-3 min at
15000 rpm (4°C). The pellet was washed with HEPES
buffer, four times and mixed with 140 μl lysis buffer
(7 M urea, 2 M thiourea, 0.4% CHAPS, 1%Ampholyte)
for 1 h with continuous shaking at room temperature.
The sample was centrifuged at 13000 rpm at 4°C for
5 min and the pull-down was solubilized in rehydration
buffer and separated by 2DE on 7 cm pH 3–10 NL
immobilized pH gradients (IPG) strips. The strips wererehydrated overnight at room temperature. Isoelectric
focusing was started at 500 V for 1 h, 1000 V for 1 h
with gradual increase to 5000 V and kept constant for a
total of 12000Vh. The gel strips equilibration and sec-
ond dimension was performed as mentioned above.Immunoblotting using S-nitrosothiol specific antibody
Total protein extracts were also used for immunoblotting
using SNO-Cys antibody. 100 μg protein was dissolved in
rehydration buffer and IPG strips (7 cm, 3–10 NL) were
rehydrated overnight. 2-DE was performed according to
the same procedure as in section of Immuno-precipitation
(IP-2D). The separated proteins were electrotransferred to
PVDF membranes at 30 mA for 2 h on Wet Blot (Bio-Rad,
USA) that later blocked with 5% TBST/milk for 1 h at
room temperature. After blocking reaction, the blot was
incubated in anti SNO-Cys antibody (1:2000) overnight at
4°C. Secondary antibody goat anti rabbit IgG HRP was ap-
plied (1:1000) for 1 h. The blots were thoroughly washed
and developed with ECL (Amersham GE), detected on ex-
posure film (Amersham GE, Sweden) and scanned with
Canon flatbed scanner (Canon, UK).Imaging and statistical analysis
Gels were analyzed by Progenesis SameSpots v4.5
(Nonlinear Dynamic, UK) according to manufacture
recommendation. Protein spots that were differentially
expressed in tissue specimen and cell line were marked.
Only spots altered consistently were selected for identifica-
tion. Statistical analysis was performed using the SPSS
statistics version 17.Immunofluorescence Staining
After de-paraffinization and rehydration by xylol different
percentage of isopropanol, heat induced antigen retrieval
was performed by immersing HCC liver section slides in a
pre-heated steamer containing citrate buffer (95-100°C)
for 30 min. Sections were blocked with Roti block (Roth,
Karlsruhe, Germany) with 1:10 dilution, later washed with
PBS (Phosphate buffer saline) and incubated with anti
CYB5A antibody (ABCAM, UK) for 1 h at 40°C. After sev-
eral steps washing membrane was incubated with se-
condary antibody, Alexa 488 anti-rabbit (ScantaCruze,
California) for 30 min. Another slide of same samples were
incubated with anti SNO-Cys antibody for 1 hr at 40°C
followed by incubation with secondary antibody, Alexa
488 anti-rabbit for 1 h while nuclei were stained with
DAPI for 2 min. Microscopic examination was performed
on Eclipse TE2000E epi-flourescence microscope (Nikon,
Japan). Images were acquired by DS-Qi1 processed using
NIS-Elements software (Nikon Japan).
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quadrupole time of flight tandem mass spectrometry
(ESI-QTOF MS/MS)
Peptide analyses were carried out on an ESI-QTOF-
tandem MS system (Waters) and in-gel digestion was
performed as described [51] with slight modification.
Briefly, gel slices were destained with the mixture of
15 mM K3Fe (CN)6 and 50 mM Na2S2O3, washed with
deionized water and dehydrated with ACN. The spots
were incubated with 100 mM ammonium bicarbonate,
washed again and vacuum dried. Proteins were in-gel
digested with sequencing grade modified trypsin (The
slices were rehydrated for digestion with 40 μl trypsin
(10 ng/ μl in 100 mM ammonium bicarbonate, pH 7.4;
Promega, Mannhein, Germany) for 45 min. Excess
trypsin solution was removed and the volume replaced
with 100 mM ammonium bicarbonate without trypsin)
overnight at 37°C. Tryptic peptides were extracted with
50% ACN/ 0.1% TFA with moderate sonication for
15 min. The extracted solutions were pooled, vacuum
dried and re-dissolved in 0.1% TFA followed by injecting
to the Q-TOF Ultima Global mass spectrometer
(Micromass, Manchester, UK) as described before [52].
The data were acquired with the MassLynx (v 4.0) soft-
ware on a Windows NT PC and further processed using
ProteinLynx Global Server (PLGS, v 2.2, Micromass,
Manchester, UK) as PKL (peak list) under the following
settings; Electrospray, centroid 80% with minimum peak
width 4 channel, noise reduction 10%, Savitzky-Golay,
MSMS, medium deisotoping with 3% threshold, no
noise reduction and no smoothing. The peak lists were
searched using the online MASCOT (http://www.
matrixscience.com) algorithm against the SwissProt
55.5 (389046 sequences; 139778124 residues).
The data were retrieved against the whole database
with search parameters set as follows: enzyme, trypsin;
allowance of up to one missed cleavage peptide; mass
tolerance ±0.5 Da and MS/MS tolerance ±0.5 Da; modi-
fications of cysteine carboamidomethylation and methio-
nine oxidation when appropriate with auto hits allowed
only significant hits to be reported.
Protein data Set and pathway enrichment analysis
Swiss-Prot accession numbers of identified differentially
expressed membrane proteins, retrieved by MASCOT
were used to investigate similarities in protein expres-
sion alterations between stages. To investigate enrich-
ment of specific pathways in the altered/PTMed protein
expression data set, “WEB-based GEneSeTAnaLysis
Toolkit” (WEBGESTALT) at http://bioinfo.vanderbilt.
edu/webgestalt/ was used [53]. Protein expression
changes are not isolated events, we therefore hypothe-
sized that differentially expressed CYB5A protein may
interact with others and play a role in oncogenesis.STRING 8.3 (http://string-db.org/) was used to explore
the biological associations among the differentially
expressed proteins [54].
Additional files
Additional file 1: Expression graphs and MS/MS of differentially
expressed proteins in HCC along with peptide sequence identified.
Additional file 2: Microscope and Camera Setting.
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